Shanghai Fosun Pharmaceutical (Group) Co(SFOSF)
$1.89-0.02 (-1.31%)
SFOSF
Shanghai Fosun Pharmaceutical (Group) Co financials statements
$1.89
At close:-0.02 (-1.31%)
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Ratios
26 Followers
Shanghai Fosun Pharmaceutical (Group) Co Ratios
SFOSF's free cash flow for Q3 2026 was ¥-834.56M. For the 2026 fiscal year, SFOSF's free cash flow was decreased by ¥-1.84B and operating cash flow was ¥1.00B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.93 | 0.92 | 1.00 | 1.06 | 1.04 |
| Quick Ratio | 0.76 | 0.73 | 0.78 | 0.85 | 0.85 |
| Cash Ratio | 0.36 | 0.36 | 0.41 | 0.49 | 0.35 |
| Solvency Ratio | 0.12 | 0.10 | 0.09 | 0.11 | 0.15 |
| Operating Cash Flow Ratio | 0.14 | 0.12 | 0.10 | 0.13 | 0.13 |
| Short-Term Operating Cash Flow Coverage | 0.24 | 0.24 | 0.23 | 0.35 | 0.42 |
| Net Current Asset Value | ¥ -24.40B | ¥ -23.04B | ¥ -23.06B | ¥ -17.78B | ¥ -14.49B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.27 | 0.27 | 0.28 | 0.26 |
| Debt-to-Equity Ratio | 0.75 | 0.67 | 0.66 | 0.68 | 0.62 |
| Debt-to-Capital Ratio | 0.43 | 0.40 | 0.40 | 0.40 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.20 | 0.18 | 0.23 | 0.22 | 0.19 |
| Financial Leverage Ratio | 2.46 | 2.49 | 2.48 | 2.40 | 2.38 |
| Debt Service Coverage Ratio | 0.23 | 0.39 | 0.45 | 0.56 | 0.75 |
| Interest Coverage Ratio | 2.06 | 2.73 | 2.50 | 8.61 | 7.68 |
| Debt to Market Cap | 0.72 | 0.82 | 0.68 | 0.43 | 0.26 |
| Interest Debt Per Share | 14.32 | 12.44 | 11.79 | 11.96 | 9.81 |
| Net Debt to EBITDA | 3.89 | 2.11 | 2.20 | 1.78 | 1.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.88% | 47.97% | 47.54% | 47.28% | 48.14% |
| EBIT Margin | 6.27% | 13.64% | 11.09% | 12.60% | 17.60% |
| EBITDA Margin | 14.96% | 20.95% | 18.25% | 17.92% | 22.30% |
| Operating Profit Margin | 6.27% | 10.34% | 7.99% | 18.88% | 16.19% |
| Pretax Profit Margin | 12.32% | 10.15% | 7.89% | 10.41% | 15.52% |
| Net Profit Margin | 8.12% | 6.74% | 5.76% | 8.49% | 12.12% |
| Continuous Operations Profit Margin | 10.24% | 8.55% | 6.99% | 8.98% | 12.76% |
| Net Income Per EBT | 65.93% | 66.44% | 73.10% | 81.56% | 78.11% |
| EBT Per EBIT | 196.42% | 98.21% | 98.70% | 55.14% | 95.88% |
| Return on Assets (ROA) | 2.73% | 2.36% | 2.10% | 3.48% | 5.07% |
| Return on Equity (ROE) | 6.74% | 5.86% | 5.22% | 8.37% | 12.07% |
| Return on Capital Employed (ROCE) | 3.03% | 5.31% | 4.15% | 11.23% | 9.87% |
| Return on Invested Capital (ROIC) | 2.00% | 3.62% | 3.11% | 8.34% | 7.09% |
| Return on Tangible Assets | 3.60% | 3.18% | 2.80% | 4.61% | 6.71% |
| Earnings Yield | 7.07% | 7.82% | 5.78% | 6.48% | 6.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.23 | 4.35 | 4.90 | 5.01 | 5.33 |
| Payables Turnover | 4.17 | 3.56 | 3.53 | 3.69 | 3.99 |
| Inventory Turnover | 3.24 | 2.94 | 2.88 | 3.37 | 3.70 |
| Fixed Asset Turnover | 1.46 | 1.75 | 1.86 | 2.74 | 2.94 |
| Asset Turnover | 0.34 | 0.35 | 0.36 | 0.41 | 0.42 |
| Working Capital Turnover Ratio | -14.52 | -28.06 | 41.07 | 28.39 | 58.78 |
| Cash Conversion Cycle | 111.37 | 105.36 | 97.72 | 82.26 | 75.84 |
| Days of Sales Outstanding | 86.21 | 83.81 | 74.56 | 72.84 | 68.47 |
| Days of Inventory Outstanding | 112.68 | 124.00 | 126.69 | 108.42 | 98.74 |
| Days of Payables Outstanding | 87.52 | 102.46 | 103.53 | 98.99 | 91.37 |
| Operating Cycle | 198.89 | 207.82 | 201.25 | 181.26 | 167.21 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.97 | 1.68 | 1.27 | 1.62 | 1.54 |
| Free Cash Flow Per Share | 0.29 | 0.02 | -0.72 | -0.64 | -0.40 |
| Dividend Paid and CapEx Coverage Ratio | 0.82 | 0.69 | 0.44 | 0.51 | 0.57 |
| Capital Expenditure Coverage Ratio | 1.17 | 1.02 | 0.64 | 0.72 | 0.79 |
| Operating Cash Flow Coverage Ratio | 0.14 | 0.14 | 0.11 | 0.14 | 0.16 |
| Operating Cash Flow to Sales Ratio | 0.13 | 0.11 | 0.08 | 0.10 | 0.10 |
| Free Cash Flow Yield | 1.65% | 0.19% | -4.65% | -2.90% | -1.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 14.16 | 12.75 | 17.31 | 15.44 | 15.12 |
| Price-to-Sales (P/S) Ratio | 1.15 | 0.86 | 1.00 | 1.31 | 1.83 |
| Price-to-Book (P/B) Ratio | 0.95 | 0.75 | 0.90 | 1.29 | 1.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 60.76 | 530.62 | -21.48 | -34.46 | -69.84 |
| Price-to-Operating Cash Flow Ratio | 8.91 | 7.92 | 12.10 | 13.66 | 18.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.74 | 0.76 | -0.46 | -0.68 | 0.51 |
| Enterprise Value Multiple | 11.58 | 6.23 | 7.66 | 9.09 | 9.82 |
| Enterprise Value | 70.02B | 53.61B | 57.89B | 71.60B | 85.44B |
| EV to EBITDA | 11.58 | 6.23 | 7.66 | 9.09 | 9.82 |
| EV to Sales | 1.73 | 1.31 | 1.40 | 1.63 | 2.19 |
| EV to Free Cash Flow | 91.55 | 802.71 | -30.11 | -42.84 | -83.45 |
| EV to Operating Cash Flow | 13.43 | 11.98 | 16.96 | 16.98 | 21.64 |
| Tangible Book Value Per Share | 12.50 | 11.11 | 10.59 | 10.67 | 9.99 |
| Shareholders’ Equity Per Share | 18.41 | 17.68 | 17.04 | 17.09 | 15.33 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.16 | 0.11 | 0.14 | 0.18 |
| Revenue Per Share | 15.28 | 15.37 | 15.44 | 16.85 | 15.26 |
| Net Income Per Share | 1.24 | 1.04 | 0.89 | 1.43 | 1.85 |
| Tax Burden | 0.66 | 0.66 | 0.73 | 0.82 | 0.78 |
| Interest Burden | 1.96 | 0.74 | 0.71 | 0.83 | 0.88 |
| Research & Development to Revenue | 0.10 | 0.09 | 0.11 | 0.10 | 0.10 |
| SG&A to Revenue | 0.17 | 0.16 | 0.11 | 0.02 | 0.02 |
| Stock-Based Compensation to Revenue | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.23 | 1.27 | 1.43 | 1.07 | 0.79 |
Currency in CNY

